{
  "docId": "019de072-ef20-75e9-922b-a59946a49f08",
  "docSlug": "b6265fe9aad535c251b3bd786fc797fa",
  "documentTitle": "BioAtla | Investor Conference Presentation Deck | 15 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 15,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a before-after comparison to illustrate the mechanism of action (healthy vs cancer cell environment).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-ef20-75e9-922b-a59946a49f08/4",
  "deckHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08",
  "deckJsonHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08.json",
  "deckAnchorHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "image",
      "text": "Diagram comparing healthy cell (no binding) vs cancer cell (CAB binding in acidic environment)",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "228d4724-6d36-4b02-beff-3dec4789c140",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "BioAtla discovered that acidic pH at the cancer cell surface unveils binding sites that are shielded at normal pH of healthy cells. BioAtla invented CAB technology, creating antibodies that bind only to these unveiled sites on cancer cells. CAB binding region is not masked or caged and thus different from prodrugs that require irreversible enzymatic cleavage to become activated. CAB antibodies have the potential for increased efficacy with improved safety relative to traditional antibodies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05a9e49d-beed-4625-a81c-0cae7821924d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.58,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L., Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2c321d1-7f82-4591-af37-a1337458f5ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Selective and targeted CAB technology widens therapeutic index, thus has the potential to enhance clinical outcomes in multiple tumor types",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef4a5153-700f-4d29-a97b-acbe28f26cac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "59651acf-0b9e-4c71-83e2-1f34906d5377",
      "evidence": "The diagram explicitly contrasts healthy cells (no binding) with cancer cells (CAB binding).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "a540d9bd-f321-42fa-8cf9-0cc0a9a8a9dc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck proposes a solution on slide 4 with Selective and targeted CAB technology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 4,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e6cab408-fc58-4534-aced-e717b9a922b7",
      "evidence": "The deck presents an executive summary and proposes a solution with Selective and targeted CAB technology",
      "position": 1,
      "objective": "Why does BioAtla's CAB technology matter?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}